EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study

Kazuki Aoyama iD, Yuya Nakajima iD, Shu Meguro iD, Yasunori Sato iD, Rei Goto iD, Mariko Hida iD, Takeshi Arimitsu iD, Yoshifumi Kasuga iD, Mamoru Tanaka iD, Hiroshi Itoh iD, Kaori Hayashi iD

JMIR mHealth and uHealth · 2026

DOI: 10.2196/72242 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR mHealth and uHealth, 2026. Verfasst von Kazuki Aoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan, 81 …. Hauptthemen laut MEDLINE: Diabetes, Gestational. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the management of gestational diabetes mellitus (GDM), the usual medical treatment requires frequent visits for glucose monitoring and insulin dose adjustment, and this imposes significant physical, psychological, and economic burdens on pregnant women. As mobile health platforms become increasingly integrated into diabetes care, telemedicine may help alleviate these burdens; however, evidence evaluating its effectiveness as a replacement for routine in-person GDM care remains limited.

Objective

This study aims to evaluate the impact of telemedicine on the quality of life and costs for patients with GDM requiring insulin therapy.

Methods

This single-center, 2-arm, randomized, open-label, parallel-group study included patients with GDM who started insulin injection therapy. Participants were randomized to either the telemedicine or standard face-to-face care groups for 10 (SD 2) weeks. The telemedicine intervention used a smartphone-linked platform that enabled the automatic transfer of glucose data from connected glucose meters and facilitated real-time video consultations. Primary end points included costs and patient satisfaction. Costs were assessed using claims data, transportation calculations, and wage-based productivity losses, while patient satisfaction was evaluated through changes in the Problem Areas in Diabetes Survey and Diabetes Therapy-Related Quality of Life questionnaire scores. Secondary outcomes included glycemic control and perinatal outcomes.

Results

In total, 38 participants were included, with 18 assigned to the telemedicine group and 20 to the standard care group. Total costs (32,712, 95% CI 15,412‐50,013 vs 59,202, 95% CI 42,603‐75,800 Japanese yen; $284, 95% CI 134‐435 vs $515, 95% CI 370‐659, purchasing power parity [PPP]–adjusted; P =.01), direct non–health care costs (922, 95% CI −240 to 2084 vs 2561, 95% CI 1447‐3676 yen; $8, 95% CI −2 to 18 vs $22, 95% CI 13 to 32 PPP-adjusted; P =.02), and indirect costs (8981, 95% CI −7119 to 25,082 vs 32,832, 95% CI 17,384‐48,279 yen; $78, 95% CI −62 to 218 vs $285, 95% CI 151‐420 PPP-adjusted; P =.01) reduced significantly in the telemedicine group compared with the standard care group. The improvements in the Problem Areas in Diabetes Survey (−7.6, 95% CI −13.7 to −1.4; P =.02) and Diabetes Therapy–Related Quality of Life domain 1 (10.5, 95% CI 0.9-20.1; P =.03) scores from the baseline were significantly greater in the telemedicine group than that in the standard care group. Nonetheless, glycemic control and frequency of perinatal complications were comparable between the 2 groups. Consultation time was similar across groups, suggesting no added workload for clinicians.

Conclusions

In this randomized trial, mobile health–enabled telemedicine safely replaced routine in-person visits for patients with GDM requiring insulin therapy. Telemedicine significantly reduced psychological and economic burdens without compromising glycemic or perinatal outcomes, demonstrating its value as a patient-centered and cost-efficient model of care. These findings support the broader implementation of mobile-based telemedicine approaches in GDM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalHumansFemalePregnancyAdultTelemedicineQuality of LifeSurveys and QuestionnairesPatient SatisfactionTreatment Outcome

Stichwörter der Autor:innen

costsgestational diabetes mellitusmobile healthpatient satisfactiontelemedicine

Autor:innen und Institutionen

  • Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan, 81 3-5363-3797.
  • Center for Preventive Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Biostatistics, Keio University School of Medicine, Tokyo, Japan.
  • Graduate School of Business Administration, Keio University,, Kanagawa, Japan.
  • Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Kazuki Aoyama, Yuya Nakajima, Shu Meguro, Yasunori Sato, Rei Goto, Mariko Hida, Takeshi Arimitsu, Yoshifumi Kasuga, Mamoru Tanaka, Hiroshi Itoh, Kaori Hayashi

Zitieren

APA

Aoyama, K., Nakajima, Y., Meguro, S., Sato, Y., Goto, R., Hida, M., Arimitsu, T., Kasuga, Y., Tanaka, M., Itoh, H., & Hayashi, K. (2026). Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study. JMIR mHealth and uHealth. https://doi.org/10.2196/72242

Vancouver

Aoyama K, Nakajima Y, Meguro S, Sato Y, Goto R, Hida M, et al. Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study. JMIR mHealth and uHealth. 2026. doi:10.2196/72242

BibTeX
@article{Aoyama2026,
  author = {Aoyama, Kazuki and Nakajima, Yuya and Meguro, Shu and Sato, Yasunori and Goto, Rei and Hida, Mariko and Arimitsu, Takeshi and Kasuga, Yoshifumi and Tanaka, Mamoru and Itoh, Hiroshi and Hayashi, Kaori},
  title = {Efficacy and Safety of a Telemedicine System in Patients With Gestational Diabetes Mellitus (TELEGLAM): Single-Center, 2-Arm, Randomized, Open-Label, Parallel-Group Study},
  journal = {JMIR mHealth and uHealth},
  year = {2026},
  doi = {10.2196/72242}
}
Kostenlos starten →